Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Invested Capital (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Invested Capital for 9 consecutive years, with $931.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 29.63% to $931.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $931.8 million, a 29.63% decrease, with the full-year FY2024 number at $1.2 billion, up 20.18% from a year prior.
  • Invested Capital was $931.8 million for Q3 2025 at Denali Therapeutics, down from $1.0 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.5 billion in Q1 2024 to a low of $812.7 million in Q3 2022.
  • A 5-year average of $1.1 billion and a median of $1.0 billion in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: skyrocketed 113.62% in 2021, then decreased 29.63% in 2025.
  • Denali Therapeutics' Invested Capital stood at $962.3 million in 2021, then increased by 8.78% to $1.0 billion in 2022, then fell by 1.52% to $1.0 billion in 2023, then grew by 20.18% to $1.2 billion in 2024, then decreased by 24.79% to $931.8 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Invested Capital are $931.8 million (Q3 2025), $1.0 billion (Q2 2025), and $1.1 billion (Q1 2025).